KRAS and cancer: A majority of SHOC2 studies in defining its role in cancer used human cancer cell lines [11, 14, 34], and only two studies involved the use of genetically modified mouse models, one for lung tumorigenesis [16], and the other for pancreatic tumorigenesis [20], both driven by oncogenic Kras mutant (KrasG12D).